| 
																	
																	
																		 David Fox
 
																		 Concepts  (485)
																		
																	 
																		Concepts are derived automatically from a person's publications. 
																			
																					
    Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
     | Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
 | Arthritis, Rheumatoid | 33 | 2024 | 1159 | 3.350 | Why? |  | CD13 Antigens | 6 | 2025 | 10 | 2.650 | Why? |  | Antigens, Differentiation, T-Lymphocyte | 9 | 2025 | 98 | 2.620 | Why? |  | Antigens, CD | 10 | 2025 | 524 | 2.360 | Why? |  | Synovial Membrane | 13 | 2022 | 117 | 2.130 | Why? |  | Scleroderma, Systemic | 7 | 2024 | 122 | 1.900 | Why? |  | Gastrostomy | 4 | 2016 | 113 | 1.650 | Why? |  | Scleroderma, Diffuse | 6 | 2022 | 10 | 1.480 | Why? |  | Fibroblasts | 15 | 2024 | 990 | 1.400 | Why? |  | Interleukin-17 | 5 | 2015 | 120 | 1.130 | Why? |  | T-Lymphocytes | 12 | 2024 | 1996 | 1.120 | Why? |  | Neoplasms | 5 | 2025 | 2655 | 0.970 | Why? |  | Fundoplication | 2 | 2016 | 54 | 0.900 | Why? |  | Th17 Cells | 5 | 2020 | 99 | 0.870 | Why? |  | Arthritis, Experimental | 7 | 2023 | 143 | 0.860 | Why? |  | Neutrophils | 5 | 2025 | 1237 | 0.820 | Why? |  | Inflammation | 12 | 2025 | 2817 | 0.820 | Why? |  | Cell Communication | 4 | 2010 | 313 | 0.810 | Why? |  | Rheumatic Diseases | 6 | 2024 | 80 | 0.770 | Why? |  | Gastroesophageal Reflux | 2 | 2016 | 235 | 0.770 | Why? |  | Enteral Nutrition | 2 | 2014 | 196 | 0.770 | Why? |  | T-Lymphocyte Subsets | 4 | 2020 | 425 | 0.740 | Why? |  | Lymphocyte Activation | 7 | 2021 | 1150 | 0.690 | Why? |  | Interleukin-4 | 2 | 2011 | 217 | 0.680 | Why? |  | Immunotherapy | 2 | 2025 | 645 | 0.670 | Why? |  | Cytokines | 10 | 2024 | 2078 | 0.600 | Why? |  | Neovascularization, Physiologic | 3 | 2019 | 176 | 0.590 | Why? |  | Tumor Necrosis Factor-alpha | 7 | 2024 | 1242 | 0.590 | Why? |  | Killer Cells, Natural | 1 | 2021 | 444 | 0.560 | Why? |  | Humans | 83 | 2025 | 136899 | 0.530 | Why? |  | Extracellular Traps | 3 | 2025 | 53 | 0.520 | Why? |  | Gastrointestinal Agents | 1 | 2016 | 65 | 0.510 | Why? |  | Decision Making | 2 | 2014 | 897 | 0.500 | Why? |  | Anti-Inflammatory Agents | 1 | 2020 | 498 | 0.500 | Why? |  | Skin | 7 | 2024 | 750 | 0.500 | Why? |  | Animals | 41 | 2025 | 36915 | 0.500 | Why? |  | Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2015 | 3 | 0.490 | Why? |  | CD8-Positive T-Lymphocytes | 2 | 2023 | 916 | 0.480 | Why? |  | Dinoprost | 1 | 2015 | 44 | 0.480 | Why? |  | Autoimmune Diseases | 5 | 2023 | 459 | 0.480 | Why? |  | Mice | 29 | 2024 | 17775 | 0.480 | Why? |  | Synoviocytes | 5 | 2022 | 16 | 0.470 | Why? |  | Cells, Cultured | 14 | 2022 | 4204 | 0.460 | Why? |  | Antigens, Neoplasm | 3 | 2024 | 321 | 0.460 | Why? |  | Immunoconjugates | 3 | 2023 | 116 | 0.450 | Why? |  | Vascular Endothelial Growth Factor A | 3 | 2018 | 543 | 0.450 | Why? |  | Chemotaxis | 1 | 2015 | 131 | 0.440 | Why? |  | Cell Adhesion Molecules | 4 | 2024 | 183 | 0.440 | Why? |  | Intubation, Gastrointestinal | 1 | 2014 | 77 | 0.440 | Why? |  | Feeding and Eating Disorders of Childhood | 1 | 2014 | 7 | 0.440 | Why? |  | Gastroscopy | 1 | 2014 | 19 | 0.440 | Why? |  | Professional-Family Relations | 2 | 2014 | 141 | 0.430 | Why? |  | MAP Kinase Kinase Kinases | 3 | 2019 | 73 | 0.430 | Why? |  | Patient Navigation | 1 | 2014 | 79 | 0.410 | Why? |  | Hospital Medicine | 1 | 2014 | 90 | 0.400 | Why? |  | Benzyl Compounds | 2 | 2024 | 3 | 0.390 | Why? |  | Antineoplastic Agents | 1 | 2024 | 2140 | 0.390 | Why? |  | Bone Resorption | 3 | 2020 | 86 | 0.380 | Why? |  | Antifungal Agents | 3 | 2022 | 137 | 0.380 | Why? |  | Autoantigens | 3 | 2020 | 429 | 0.380 | Why? |  | Azetidines | 2 | 2024 | 42 | 0.380 | Why? |  | Fibrosis | 4 | 2024 | 552 | 0.380 | Why? |  | Multiple Sclerosis, Chronic Progressive | 2 | 2024 | 28 | 0.370 | Why? |  | Growth Inhibitors | 1 | 2011 | 43 | 0.370 | Why? |  | Antigen-Presenting Cells | 3 | 2010 | 156 | 0.360 | Why? |  | Multiple Sclerosis | 3 | 2024 | 451 | 0.360 | Why? |  | Receptors, Interleukin-4 | 1 | 2011 | 16 | 0.360 | Why? |  | CD4-Positive T-Lymphocytes | 4 | 2023 | 1092 | 0.350 | Why? |  | Cryptococcus neoformans | 2 | 2022 | 21 | 0.350 | Why? |  | Endothelial Cells | 5 | 2019 | 779 | 0.350 | Why? |  | General Surgery | 1 | 2012 | 170 | 0.340 | Why? |  | Teaching Rounds | 1 | 2011 | 67 | 0.340 | Why? |  | Tacrolimus | 2 | 2022 | 199 | 0.320 | Why? |  | Molecular Targeted Therapy | 4 | 2018 | 413 | 0.320 | Why? |  | Ulna | 1 | 2009 | 29 | 0.310 | Why? |  | Uveitis | 2 | 2022 | 130 | 0.310 | Why? |  | B7-1 Antigen | 2 | 2010 | 58 | 0.310 | Why? |  | Male | 35 | 2025 | 67308 | 0.310 | Why? |  | Inhibitor of Differentiation Protein 1 | 2 | 2019 | 8 | 0.290 | Why? |  | Immune System Diseases | 1 | 2008 | 39 | 0.290 | Why? |  | Female | 35 | 2025 | 72703 | 0.280 | Why? |  | Pediatrics | 2 | 2014 | 1119 | 0.280 | Why? |  | Benzamides | 2 | 2019 | 218 | 0.280 | Why? |  | Silicones | 3 | 2017 | 25 | 0.280 | Why? |  | Hospitals, Pediatric | 1 | 2011 | 533 | 0.280 | Why? |  | Benzimidazoles | 2 | 2019 | 169 | 0.280 | Why? |  | CD40 Ligand | 1 | 2007 | 41 | 0.270 | Why? |  | Ligands | 3 | 2025 | 665 | 0.270 | Why? |  | Cell Differentiation | 4 | 2019 | 1976 | 0.270 | Why? |  | Collagen Type II | 3 | 2020 | 53 | 0.270 | Why? |  | Macrophages | 4 | 2019 | 1547 | 0.260 | Why? |  | Family | 1 | 2011 | 667 | 0.260 | Why? |  | Receptors, Immunologic | 1 | 2008 | 223 | 0.260 | Why? |  | Encephalomyelitis, Autoimmune, Experimental | 2 | 2017 | 68 | 0.260 | Why? |  | Antibodies, Monoclonal | 4 | 2024 | 1417 | 0.260 | Why? |  | Drug Design | 2 | 2019 | 170 | 0.250 | Why? |  | Nipecotic Acids | 2 | 2017 | 5 | 0.250 | Why? |  | Postoperative Complications | 2 | 2014 | 2627 | 0.240 | Why? |  | Polymorphism, Single Nucleotide | 2 | 2023 | 2175 | 0.230 | Why? |  | Abatacept | 3 | 2022 | 53 | 0.230 | Why? |  | Osteoblasts | 1 | 2005 | 126 | 0.230 | Why? |  | Antigen Presentation | 2 | 2020 | 216 | 0.230 | Why? |  | Hyaluronan Receptors | 1 | 2025 | 103 | 0.220 | Why? |  | Middle Aged | 18 | 2025 | 33118 | 0.220 | Why? |  | Antibodies, Antiphospholipid | 1 | 2024 | 28 | 0.220 | Why? |  | Signal Transduction | 6 | 2024 | 5077 | 0.220 | Why? |  | Actomyosin | 1 | 2024 | 18 | 0.220 | Why? |  | Benzylisoquinolines | 1 | 2023 | 2 | 0.220 | Why? |  | Arthroplasty, Replacement | 2 | 2015 | 40 | 0.220 | Why? |  | Delivery of Health Care | 1 | 2011 | 948 | 0.220 | Why? |  | Antiphospholipid Syndrome | 1 | 2024 | 38 | 0.210 | Why? |  | Cell Membrane | 1 | 2007 | 751 | 0.210 | Why? |  | Tacrolimus Binding Protein 1A | 2 | 2022 | 10 | 0.210 | Why? |  | Lymphoma, T-Cell | 1 | 2023 | 25 | 0.210 | Why? |  | Mice, Inbred DBA | 4 | 2020 | 196 | 0.210 | Why? |  | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 51 | 0.210 | Why? |  | Arthroplasty, Replacement, Finger | 2 | 2014 | 3 | 0.210 | Why? |  | Calcineurin Inhibitors | 2 | 2022 | 72 | 0.200 | Why? |  | Primary Health Care | 2 | 2019 | 1741 | 0.200 | Why? |  | Optic Neuritis | 1 | 2023 | 41 | 0.200 | Why? |  | Retinal Pigments | 1 | 2022 | 6 | 0.200 | Why? |  | Sulfatases | 1 | 2022 | 4 | 0.200 | Why? |  | Neuroprotective Agents | 1 | 2024 | 132 | 0.200 | Why? |  | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2022 | 45 | 0.200 | Why? |  | Calcineurin | 2 | 2022 | 108 | 0.200 | Why? |  | Psoriasis | 1 | 2023 | 102 | 0.200 | Why? |  | Mice, SCID | 2 | 2021 | 367 | 0.200 | Why? |  | Coculture Techniques | 3 | 2008 | 240 | 0.190 | Why? |  | Osteoarthritis | 3 | 2019 | 185 | 0.190 | Why? |  | Genetic Predisposition to Disease | 1 | 2011 | 2416 | 0.190 | Why? |  | Mice, Inbred C57BL | 10 | 2019 | 5766 | 0.190 | Why? |  | Phagocytosis | 2 | 2023 | 379 | 0.180 | Why? |  | Adult | 14 | 2025 | 37595 | 0.180 | Why? |  | Lymphocytes | 1 | 2024 | 393 | 0.180 | Why? |  | Adaptor Proteins, Signal Transducing | 2 | 2015 | 429 | 0.180 | Why? |  | Graft vs Host Disease | 1 | 2023 | 248 | 0.180 | Why? |  | Transforming Growth Factor beta | 3 | 2024 | 480 | 0.180 | Why? |  | Quantitative Trait Loci | 1 | 2023 | 381 | 0.180 | Why? |  | Mice, Transgenic | 5 | 2020 | 2182 | 0.180 | Why? |  | Cell Line, Tumor | 4 | 2023 | 3396 | 0.170 | Why? |  | Lymphocyte Subsets | 1 | 2021 | 87 | 0.170 | Why? |  | Hemeproteins | 1 | 2020 | 8 | 0.170 | Why? |  | Malassezia | 1 | 2020 | 6 | 0.170 | Why? |  | Colitis | 1 | 2023 | 255 | 0.170 | Why? |  | GTP Phosphohydrolases | 1 | 2021 | 91 | 0.170 | Why? |  | B-Lymphocytes | 2 | 2020 | 844 | 0.170 | Why? |  | Receptors, Lysosphingolipid | 1 | 2020 | 15 | 0.170 | Why? |  | Patient Readmission | 2 | 2016 | 693 | 0.170 | Why? |  | Joint Prosthesis | 2 | 2017 | 20 | 0.160 | Why? |  | Receptors, Cytokine | 1 | 2020 | 36 | 0.160 | Why? |  | Arthroplasty | 2 | 2017 | 48 | 0.160 | Why? |  | Neovascularization, Pathologic | 2 | 2020 | 300 | 0.160 | Why? |  | Retina | 2 | 2022 | 298 | 0.160 | Why? |  | Disease Models, Animal | 9 | 2022 | 4281 | 0.160 | Why? |  | Transcription, Genetic | 2 | 2018 | 1458 | 0.160 | Why? |  | Aspergillus fumigatus | 1 | 2019 | 26 | 0.160 | Why? |  | Complement C3-C5 Convertases | 1 | 2019 | 24 | 0.160 | Why? |  | Citrullination | 1 | 2019 | 13 | 0.160 | Why? |  | Tumor Microenvironment | 1 | 2024 | 682 | 0.160 | Why? |  | Histones | 2 | 2022 | 639 | 0.160 | Why? |  | Phosphodiesterase 4 Inhibitors | 1 | 2019 | 5 | 0.160 | Why? |  | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2019 | 10 | 0.160 | Why? |  | Medicare | 2 | 2015 | 745 | 0.160 | Why? |  | Interferons | 1 | 2021 | 199 | 0.160 | Why? |  | Metacarpophalangeal Joint | 3 | 2014 | 15 | 0.160 | Why? |  | Complement C5 | 1 | 2019 | 81 | 0.160 | Why? |  | Angiogenesis Inducing Agents | 1 | 2019 | 24 | 0.160 | Why? |  | Interleukin-7 | 1 | 2019 | 61 | 0.150 | Why? |  | Aged | 11 | 2025 | 23641 | 0.150 | Why? |  | Infant, Newborn | 3 | 2016 | 6043 | 0.150 | Why? |  | Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 51 | 0.150 | Why? |  | Fragile X Syndrome | 1 | 2019 | 84 | 0.150 | Why? |  | Patient-Centered Care | 2 | 2014 | 523 | 0.150 | Why? |  | Interleukin-11 | 1 | 2018 | 10 | 0.150 | Why? |  | Complement C3 | 1 | 2019 | 210 | 0.140 | Why? |  | Microfilament Proteins | 1 | 2019 | 131 | 0.140 | Why? |  | Child, Preschool | 5 | 2016 | 11013 | 0.140 | Why? |  | Anti-Citrullinated Protein Antibodies | 1 | 2019 | 113 | 0.140 | Why? |  | DNA-Binding Proteins | 2 | 2017 | 1502 | 0.140 | Why? |  | Leukocytes, Mononuclear | 1 | 2021 | 557 | 0.140 | Why? |  | Brain Diseases | 1 | 2019 | 141 | 0.140 | Why? |  | Receptors, G-Protein-Coupled | 2 | 2022 | 221 | 0.140 | Why? |  | Prospective Studies | 7 | 2021 | 7543 | 0.140 | Why? |  | Hemolysis | 1 | 2019 | 205 | 0.140 | Why? |  | Infant | 4 | 2016 | 9408 | 0.140 | Why? |  | Rho Factor | 1 | 2017 | 4 | 0.140 | Why? |  | Chemotactic Factors | 1 | 2017 | 56 | 0.130 | Why? |  | Peripheral Nervous System Diseases | 1 | 2018 | 129 | 0.130 | Why? |  | Antirheumatic Agents | 5 | 2019 | 290 | 0.130 | Why? |  | Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 36 | 0.130 | Why? |  | MicroRNAs | 1 | 2024 | 703 | 0.130 | Why? |  | Joints | 1 | 2018 | 105 | 0.130 | Why? |  | Oncogene Proteins | 1 | 2017 | 59 | 0.130 | Why? |  | North Carolina | 1 | 2016 | 105 | 0.130 | Why? |  | Cartilage, Articular | 1 | 2020 | 309 | 0.130 | Why? |  | Crystallography, X-Ray | 4 | 2020 | 474 | 0.130 | Why? |  | Internationality | 1 | 2017 | 155 | 0.130 | Why? |  | Arthritis, Juvenile | 1 | 2017 | 55 | 0.130 | Why? |  | Surveys and Questionnaires | 6 | 2024 | 5730 | 0.130 | Why? |  | Chromosomal Proteins, Non-Histone | 1 | 2017 | 130 | 0.130 | Why? |  | Enzyme-Linked Immunosorbent Assay | 4 | 2024 | 849 | 0.120 | Why? |  | Aptamers, Nucleotide | 1 | 2017 | 83 | 0.120 | Why? |  | Toll-Like Receptors | 1 | 2016 | 186 | 0.120 | Why? |  | Child | 6 | 2016 | 21896 | 0.120 | Why? |  | Postoperative Period | 1 | 2016 | 344 | 0.120 | Why? |  | Adolescent | 7 | 2020 | 21402 | 0.120 | Why? |  | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2015 | 34 | 0.120 | Why? |  | Emergency Treatment | 1 | 2016 | 117 | 0.120 | Why? |  | Laminin | 1 | 2015 | 69 | 0.120 | Why? |  | Hand Joints | 1 | 2015 | 5 | 0.120 | Why? |  | Oxidative Stress | 3 | 2020 | 1302 | 0.120 | Why? |  | Histone Deacetylases | 1 | 2016 | 215 | 0.120 | Why? |  | Proteoglycans | 1 | 2015 | 107 | 0.120 | Why? |  | Protein Kinase Inhibitors | 2 | 2019 | 919 | 0.120 | Why? |  | Nitric Oxide | 1 | 2020 | 914 | 0.120 | Why? |  | Glucocorticoids | 1 | 2019 | 596 | 0.120 | Why? |  | Autoimmunity | 1 | 2021 | 893 | 0.120 | Why? |  | Complement System Proteins | 1 | 2018 | 328 | 0.120 | Why? |  | Transcriptional Activation | 1 | 2017 | 379 | 0.110 | Why? |  | rho-Associated Kinases | 1 | 2015 | 85 | 0.110 | Why? |  | Antibodies, Anti-Idiotypic | 1 | 2015 | 59 | 0.110 | Why? |  | Membrane Glycoproteins | 1 | 2017 | 501 | 0.110 | Why? |  | Synovial Fluid | 3 | 2019 | 69 | 0.110 | Why? |  | Cell Movement | 2 | 2019 | 971 | 0.110 | Why? |  | Drug Combinations | 1 | 2015 | 339 | 0.110 | Why? |  | Wrist Joint | 1 | 2015 | 65 | 0.110 | Why? |  | Serum Response Factor | 1 | 2014 | 33 | 0.110 | Why? |  | Ultrasonography | 1 | 2018 | 749 | 0.110 | Why? |  | Mice, Knockout | 5 | 2020 | 2998 | 0.110 | Why? |  | Thioctic Acid | 1 | 2014 | 11 | 0.110 | Why? |  | Dermis | 1 | 2014 | 33 | 0.110 | Why? |  | Hand Deformities, Acquired | 1 | 2013 | 1 | 0.110 | Why? |  | Upper Extremity | 1 | 2015 | 100 | 0.110 | Why? |  | Phosphorylation | 2 | 2015 | 1762 | 0.110 | Why? |  | CD3 Complex | 2 | 2024 | 106 | 0.110 | Why? |  | Patient Care Planning | 1 | 2014 | 154 | 0.100 | Why? |  | Bacteria | 1 | 2020 | 855 | 0.100 | Why? |  | Interleukin-6 | 3 | 2017 | 771 | 0.100 | Why? |  | Collagen | 1 | 2015 | 446 | 0.100 | Why? |  | Antitubercular Agents | 1 | 2014 | 206 | 0.100 | Why? |  | Congresses as Topic | 1 | 2014 | 229 | 0.100 | Why? |  | Adrenal Cortex Hormones | 1 | 2016 | 552 | 0.100 | Why? |  | Retrospective Studies | 5 | 2019 | 15514 | 0.100 | Why? |  | Blotting, Western | 4 | 2016 | 1227 | 0.100 | Why? |  | Myofibroblasts | 1 | 2014 | 125 | 0.100 | Why? |  | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 234 | 0.100 | Why? |  | Patient Participation | 2 | 2014 | 423 | 0.100 | Why? |  | Infant, Premature | 1 | 2016 | 563 | 0.100 | Why? |  | Cell Death | 2 | 2024 | 370 | 0.100 | Why? |  | Osteoclasts | 3 | 2019 | 52 | 0.100 | Why? |  | Autoantibodies | 4 | 2023 | 1498 | 0.100 | Why? |  | Length of Stay | 2 | 2015 | 1203 | 0.100 | Why? |  | Oncogene Proteins, Fusion | 1 | 2014 | 213 | 0.090 | Why? |  | Cell Proliferation | 5 | 2019 | 2471 | 0.090 | Why? |  | Lung | 1 | 2025 | 4046 | 0.090 | Why? |  | STAT6 Transcription Factor | 1 | 2011 | 27 | 0.090 | Why? |  | Health Services Research | 1 | 2014 | 403 | 0.090 | Why? |  | GATA3 Transcription Factor | 1 | 2011 | 26 | 0.090 | Why? |  | Factor Analysis, Statistical | 1 | 2012 | 287 | 0.090 | Why? |  | Mycobacterium tuberculosis | 1 | 2014 | 317 | 0.090 | Why? |  | Health Care Costs | 1 | 2014 | 386 | 0.090 | Why? |  | Recombinant Proteins | 1 | 2015 | 1357 | 0.090 | Why? |  | Outpatients | 1 | 2015 | 393 | 0.090 | Why? |  | Antibodies, Monoclonal, Humanized | 1 | 2017 | 803 | 0.090 | Why? |  | Severity of Illness Index | 3 | 2019 | 2833 | 0.090 | Why? |  | United States | 6 | 2024 | 14595 | 0.090 | Why? |  | Lower Extremity | 1 | 2015 | 423 | 0.090 | Why? |  | Real-Time Polymerase Chain Reaction | 3 | 2016 | 344 | 0.090 | Why? |  | Medicaid | 1 | 2015 | 433 | 0.090 | Why? |  | Practice Patterns, Physicians' | 1 | 2019 | 1310 | 0.090 | Why? |  | Bleomycin | 2 | 2024 | 247 | 0.090 | Why? |  | Th2 Cells | 1 | 2011 | 176 | 0.080 | Why? |  | Treatment Outcome | 6 | 2019 | 10768 | 0.080 | Why? |  | Young Adult | 5 | 2020 | 13157 | 0.080 | Why? |  | Immunophenotyping | 1 | 2011 | 318 | 0.080 | Why? |  | Interferon-gamma | 2 | 2019 | 790 | 0.080 | Why? |  | Hospitalists | 1 | 2014 | 243 | 0.080 | Why? |  | STAT3 Transcription Factor | 1 | 2011 | 202 | 0.080 | Why? |  | Cell Separation | 1 | 2011 | 319 | 0.080 | Why? |  | Quality of Life | 2 | 2018 | 2847 | 0.080 | Why? |  | Focus Groups | 1 | 2011 | 500 | 0.070 | Why? |  | Mice, Inbred BALB C | 1 | 2011 | 1271 | 0.070 | Why? |  | Receptors, Pattern Recognition | 1 | 2008 | 12 | 0.070 | Why? |  | Inhibitory Concentration 50 | 2 | 2019 | 90 | 0.070 | Why? |  | Rheumatology | 2 | 2019 | 119 | 0.070 | Why? |  | B7 Antigens | 1 | 2008 | 14 | 0.070 | Why? |  | Th1 Cells | 2 | 2020 | 143 | 0.070 | Why? |  | CD28 Antigens | 2 | 2022 | 53 | 0.070 | Why? |  | Immunoglobulin G | 2 | 2024 | 886 | 0.070 | Why? |  | Lipopolysaccharides | 2 | 2023 | 882 | 0.070 | Why? |  | Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 31 | 0.070 | Why? |  | Cohort Studies | 5 | 2017 | 5711 | 0.070 | Why? |  | Rats | 3 | 2024 | 5675 | 0.070 | Why? |  | Gram-Positive Bacterial Infections | 1 | 2008 | 68 | 0.070 | Why? |  | Mycoses | 1 | 2008 | 80 | 0.070 | Why? |  | Intercellular Adhesion Molecule-1 | 1 | 2007 | 139 | 0.070 | Why? |  | Structure-Activity Relationship | 2 | 2019 | 586 | 0.070 | Why? |  | Hybridomas | 1 | 2007 | 237 | 0.070 | Why? |  | Gene Expression | 3 | 2019 | 1505 | 0.070 | Why? |  | Models, Animal | 2 | 2019 | 387 | 0.070 | Why? |  | CD4 Antigens | 1 | 2007 | 141 | 0.070 | Why? |  | Molecular Dynamics Simulation | 2 | 2019 | 237 | 0.060 | Why? |  | Colorado | 1 | 2016 | 4491 | 0.060 | Why? |  | Receptors, Antigen, T-Cell | 1 | 2010 | 719 | 0.060 | Why? |  | Cell Adhesion | 1 | 2007 | 466 | 0.060 | Why? |  | Interleukin-2 | 1 | 2007 | 455 | 0.060 | Why? |  | Follow-Up Studies | 4 | 2017 | 5126 | 0.060 | Why? |  | RNA, Messenger | 3 | 2021 | 2837 | 0.060 | Why? |  | Virus Diseases | 1 | 2008 | 216 | 0.060 | Why? |  | Genotype | 1 | 2011 | 1906 | 0.060 | Why? |  | Pilot Projects | 1 | 2011 | 1684 | 0.060 | Why? |  | Cell Line, Transformed | 1 | 2005 | 145 | 0.060 | Why? |  | Histocompatibility Antigens Class II | 1 | 2007 | 368 | 0.060 | Why? |  | Protein Binding | 1 | 2011 | 2222 | 0.060 | Why? |  | Binding Sites | 2 | 2019 | 1308 | 0.060 | Why? |  | Aged, 80 and over | 3 | 2015 | 7552 | 0.060 | Why? |  | Double-Blind Method | 2 | 2020 | 1980 | 0.060 | Why? |  | Matrix Metalloproteinase 14 | 1 | 2024 | 3 | 0.060 | Why? |  | beta 2-Glycoprotein I | 1 | 2024 | 6 | 0.060 | Why? |  | X-Ray Microtomography | 2 | 2015 | 94 | 0.060 | Why? |  | Down-Regulation | 2 | 2017 | 658 | 0.060 | Why? |  | Laboratory Proficiency Testing | 1 | 2024 | 10 | 0.060 | Why? |  | NFATC Transcription Factors | 2 | 2015 | 95 | 0.060 | Why? |  | Administration, Oral | 2 | 2017 | 811 | 0.060 | Why? |  | Pathologists | 1 | 2024 | 18 | 0.060 | Why? |  | Graft Rejection | 1 | 2008 | 623 | 0.060 | Why? |  | Inflammation Mediators | 2 | 2017 | 514 | 0.050 | Why? |  | Parents | 1 | 2012 | 1361 | 0.050 | Why? |  | Immunoassay | 1 | 2024 | 114 | 0.050 | Why? |  | Collagen Type I | 2 | 2014 | 133 | 0.050 | Why? |  | Plasma Cells | 1 | 2023 | 71 | 0.050 | Why? |  | Mutation | 1 | 2014 | 3948 | 0.050 | Why? |  | Asthma | 1 | 2016 | 2285 | 0.050 | Why? |  | Trans-Activators | 2 | 2017 | 399 | 0.050 | Why? |  | Pantothenic Acid | 1 | 2022 | 6 | 0.050 | Why? |  | T-Lymphocytes, Cytotoxic | 1 | 2023 | 173 | 0.050 | Why? |  | Immunoglobulin M | 1 | 2024 | 287 | 0.050 | Why? |  | Cytoskeleton | 1 | 2024 | 186 | 0.050 | Why? |  | Receptor, Bradykinin B1 | 1 | 2022 | 2 | 0.050 | Why? |  | Gene Expression Profiling | 2 | 2020 | 1769 | 0.050 | Why? |  | Reference Values | 1 | 2024 | 820 | 0.050 | Why? |  | Models, Molecular | 2 | 2020 | 1586 | 0.050 | Why? |  | Bradykinin | 1 | 2022 | 46 | 0.050 | Why? |  | Immunosuppressive Agents | 2 | 2022 | 886 | 0.050 | Why? |  | Protein Kinase C-delta | 1 | 2022 | 49 | 0.050 | Why? |  | Transcription Factor AP-1 | 1 | 2022 | 92 | 0.050 | Why? |  | JNK Mitogen-Activated Protein Kinases | 1 | 2022 | 163 | 0.050 | Why? |  | Tight Junctions | 1 | 2022 | 77 | 0.050 | Why? |  | Receptors, Tumor Necrosis Factor | 1 | 2022 | 164 | 0.050 | Why? |  | Cell Line | 2 | 2017 | 2847 | 0.050 | Why? |  | Fungi | 1 | 2022 | 148 | 0.040 | Why? |  | Virulence Factors | 1 | 2022 | 167 | 0.040 | Why? |  | Ergosterol | 1 | 2020 | 1 | 0.040 | Why? |  | Gene Transfer, Horizontal | 1 | 2020 | 34 | 0.040 | Why? |  | Xenograft Model Antitumor Assays | 1 | 2023 | 857 | 0.040 | Why? |  | Interleukin-1 Receptor-Associated Kinases | 1 | 2020 | 30 | 0.040 | Why? |  | RNA, Small Interfering | 1 | 2022 | 620 | 0.040 | Why? |  | Citrulline | 1 | 2020 | 45 | 0.040 | Why? |  | Coccidioides | 1 | 2019 | 5 | 0.040 | Why? |  | Longitudinal Studies | 2 | 2019 | 2844 | 0.040 | Why? |  | Visual Analog Scale | 1 | 2019 | 33 | 0.040 | Why? |  | Georgia | 1 | 2019 | 84 | 0.040 | Why? |  | Mice, Inbred A | 1 | 2019 | 49 | 0.040 | Why? |  | Gene Expression Regulation, Fungal | 1 | 2020 | 73 | 0.040 | Why? |  | Biopsy | 1 | 2023 | 1130 | 0.040 | Why? |  | Fungal Proteins | 1 | 2020 | 134 | 0.040 | Why? |  | Interleukin-12 | 1 | 2020 | 121 | 0.040 | Why? |  | Aspergillosis | 1 | 2019 | 22 | 0.040 | Why? |  | U937 Cells | 1 | 2019 | 25 | 0.040 | Why? |  | Placebos | 1 | 2020 | 207 | 0.040 | Why? |  | Candida albicans | 1 | 2019 | 56 | 0.040 | Why? |  | Cross-Sectional Studies | 1 | 2011 | 5398 | 0.040 | Why? |  | Receptors, Interleukin-7 | 1 | 2019 | 28 | 0.040 | Why? |  | Symbiosis | 1 | 2020 | 80 | 0.040 | Why? |  | Cryptococcosis | 1 | 2019 | 27 | 0.040 | Why? |  | Ankle Joint | 1 | 2020 | 110 | 0.040 | Why? |  | Epigenetic Repression | 1 | 2019 | 4 | 0.040 | Why? |  | Patient Discharge | 2 | 2016 | 887 | 0.040 | Why? |  | Mice, Inbred ICR | 1 | 2019 | 120 | 0.040 | Why? |  | Allosteric Regulation | 1 | 2019 | 97 | 0.040 | Why? |  | Infliximab | 1 | 2019 | 105 | 0.040 | Why? |  | Vital Capacity | 1 | 2019 | 309 | 0.040 | Why? |  | Gene Deletion | 1 | 2020 | 393 | 0.040 | Why? |  | Drug Discovery | 1 | 2019 | 141 | 0.040 | Why? |  | Methylation | 1 | 2019 | 237 | 0.040 | Why? |  | Gene Expression Regulation | 2 | 2019 | 2615 | 0.040 | Why? |  | Receptors, Notch | 1 | 2019 | 86 | 0.040 | Why? |  | Image-Guided Biopsy | 1 | 2018 | 39 | 0.040 | Why? |  | Interleukin-11 Receptor alpha Subunit | 1 | 2018 | 4 | 0.040 | Why? |  | Bone Marrow Cells | 1 | 2019 | 313 | 0.040 | Why? |  | Cell Cycle Proteins | 1 | 2022 | 614 | 0.040 | Why? |  | Hemoglobins | 1 | 2020 | 356 | 0.040 | Why? |  | Myeloid Cells | 1 | 2019 | 146 | 0.040 | Why? |  | Transendothelial and Transepithelial Migration | 1 | 2018 | 31 | 0.040 | Why? |  | Nerve Fibers | 1 | 2018 | 96 | 0.040 | Why? |  | Rats, Inbred F344 | 1 | 2018 | 264 | 0.040 | Why? |  | Molecular Structure | 1 | 2019 | 508 | 0.030 | Why? |  | A549 Cells | 1 | 2017 | 64 | 0.030 | Why? |  | Serum Response Element | 1 | 2017 | 6 | 0.030 | Why? |  | Adoptive Transfer | 1 | 2018 | 224 | 0.030 | Why? |  | Nuclear Proteins | 1 | 2022 | 703 | 0.030 | Why? |  | Zymosan | 1 | 2017 | 65 | 0.030 | Why? |  | Hyperalgesia | 1 | 2018 | 125 | 0.030 | Why? |  | Follistatin-Related Proteins | 1 | 2016 | 2 | 0.030 | Why? |  | Nectins | 1 | 2016 | 6 | 0.030 | Why? |  | Cysteine-Rich Protein 61 | 1 | 2016 | 7 | 0.030 | Why? |  | Sequence Analysis, RNA | 1 | 2019 | 451 | 0.030 | Why? |  | Paclitaxel | 1 | 2018 | 231 | 0.030 | Why? |  | Interleukin-8 | 1 | 2018 | 269 | 0.030 | Why? |  | Genome-Wide Association Study | 1 | 2023 | 1434 | 0.030 | Why? |  | Fibroblast Growth Factor 2 | 1 | 2016 | 87 | 0.030 | Why? |  | Primary Cell Culture | 1 | 2017 | 172 | 0.030 | Why? |  | Neuralgia | 1 | 2018 | 134 | 0.030 | Why? |  | Monocytes | 1 | 2019 | 567 | 0.030 | Why? |  | Phylogeny | 1 | 2020 | 897 | 0.030 | Why? |  | Healthy Volunteers | 1 | 2017 | 204 | 0.030 | Why? |  | Evolution, Molecular | 1 | 2020 | 488 | 0.030 | Why? |  | Knee Joint | 1 | 2019 | 400 | 0.030 | Why? |  | Patient Reported Outcome Measures | 1 | 2019 | 398 | 0.030 | Why? |  | Calcium | 1 | 2022 | 1233 | 0.030 | Why? |  | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.030 | Why? |  | Gene Knockdown Techniques | 1 | 2016 | 329 | 0.030 | Why? |  | Behavior, Animal | 1 | 2019 | 513 | 0.030 | Why? |  | DNA | 1 | 2022 | 1460 | 0.030 | Why? |  | Fluorescent Antibody Technique | 1 | 2016 | 386 | 0.030 | Why? |  | Interleukin-1beta | 1 | 2017 | 371 | 0.030 | Why? |  | Quantitative Structure-Activity Relationship | 1 | 2014 | 18 | 0.030 | Why? |  | Protein Structure, Tertiary | 1 | 2017 | 869 | 0.030 | Why? |  | Arthrodesis | 1 | 2015 | 31 | 0.030 | Why? |  | RANK Ligand | 1 | 2014 | 29 | 0.030 | Why? |  | Pregnancy Complications | 1 | 2019 | 521 | 0.030 | Why? |  | Databases, Protein | 1 | 2014 | 86 | 0.030 | Why? |  | HEK293 Cells | 1 | 2017 | 734 | 0.030 | Why? |  | Connective Tissue Growth Factor | 1 | 2014 | 25 | 0.030 | Why? |  | Spinal Cord | 1 | 2017 | 369 | 0.030 | Why? |  | Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 4 | 0.030 | Why? |  | Neoplasm Proteins | 1 | 2017 | 432 | 0.030 | Why? |  | Lymphoid Tissue | 1 | 2014 | 75 | 0.030 | Why? |  | Sulfurtransferases | 1 | 2014 | 10 | 0.030 | Why? |  | Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 15 | 0.030 | Why? |  | Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 18 | 0.030 | Why? |  | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 23 | 0.030 | Why? |  | NIH 3T3 Cells | 1 | 2014 | 144 | 0.030 | Why? |  | Transcription Factors | 1 | 2022 | 1715 | 0.030 | Why? |  | Databases, Factual | 1 | 2019 | 1345 | 0.030 | Why? |  | Up-Regulation | 1 | 2016 | 846 | 0.030 | Why? |  | Lysophospholipids | 1 | 2014 | 80 | 0.030 | Why? |  | Plasminogen Activator Inhibitor 1 | 1 | 2014 | 86 | 0.030 | Why? |  | Species Specificity | 1 | 2014 | 593 | 0.030 | Why? |  | Amino Acid Substitution | 1 | 2014 | 309 | 0.030 | Why? |  | Mycobacterium | 1 | 2014 | 109 | 0.030 | Why? |  | Multicenter Studies as Topic | 1 | 2014 | 303 | 0.030 | Why? |  | Matrix Metalloproteinases | 1 | 2014 | 94 | 0.030 | Why? |  | Biomimetic Materials | 1 | 2013 | 72 | 0.030 | Why? |  | Enzyme Activation | 1 | 2014 | 816 | 0.030 | Why? |  | Cartilage | 1 | 2014 | 188 | 0.030 | Why? |  | Rats, Sprague-Dawley | 1 | 2018 | 2500 | 0.020 | Why? |  | Reoperation | 1 | 2015 | 568 | 0.020 | Why? |  | Membrane Proteins | 1 | 2019 | 1167 | 0.020 | Why? |  | Immunity, Innate | 1 | 2018 | 832 | 0.020 | Why? |  | Immunohistochemistry | 1 | 2016 | 1739 | 0.020 | Why? |  | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 974 | 0.020 | Why? |  | Cell Culture Techniques | 1 | 2014 | 363 | 0.020 | Why? |  | Multivariate Analysis | 1 | 2015 | 1524 | 0.020 | Why? |  | Range of Motion, Articular | 1 | 2013 | 387 | 0.020 | Why? |  | Linear Models | 1 | 2013 | 850 | 0.020 | Why? |  | Patient Satisfaction | 1 | 2014 | 657 | 0.020 | Why? |  | Hand Strength | 1 | 2011 | 122 | 0.020 | Why? |  | International Classification of Diseases | 1 | 2011 | 131 | 0.020 | Why? |  | Computational Biology | 1 | 2014 | 644 | 0.020 | Why? |  | Patient Education as Topic | 1 | 2014 | 762 | 0.020 | Why? |  | Genomics | 1 | 2014 | 790 | 0.020 | Why? |  | Models, Statistical | 1 | 2013 | 667 | 0.020 | Why? |  | Disability Evaluation | 1 | 2011 | 291 | 0.020 | Why? |  | Prognosis | 1 | 2017 | 4011 | 0.020 | Why? |  | Bacterial Proteins | 1 | 2014 | 889 | 0.020 | Why? |  | Incidence | 1 | 2015 | 2783 | 0.020 | Why? |  | Pregnancy | 1 | 2019 | 6715 | 0.020 | Why? |  | Time Factors | 1 | 2017 | 6802 | 0.020 | Why? |  | Socioeconomic Factors | 1 | 2011 | 1279 | 0.020 | Why? |  | Clinical Trials as Topic | 1 | 2010 | 1037 | 0.010 | Why? |  | Emergency Service, Hospital | 1 | 2016 | 2033 | 0.010 | Why? |  | Breast Neoplasms | 1 | 2017 | 2243 | 0.010 | Why? |  | Apoptosis | 1 | 2013 | 2542 | 0.010 | Why? |  | Risk Factors | 1 | 2015 | 10313 | 0.010 | Why? | 
 | 
																	
																		
																			
																					
    Fox's Networks
 
Click the "See All" links for more information and interactive visualizations!
 Concepts  Derived automatically from this person's publications._ Co-Authors  People in Profiles who have published with this person._ Similar People  People who share similar concepts with this person._ 
            
                Same Department   
				People who are also in this person's primary department.
			 Physical Neighbors  People whose addresses are nearby this person._ |